News

Aastrom Biosciences will acquire Sanofi's CTRM business for $6.5 million.

Novartis receives FDA breakthrough therapy designation for Bexsero, a meningitis B vaccine.

Immunovaccine's vaccine technology chosen for cervical, head, and neck cancer trials conducted by Dana-Farber Institute.

EMA notifies EU healthcare professionals of the falsified cancer drug Herceptin.

Mallinckrodt will acquire Questcor to create a diversified, high-growth specialty pharmaceuticals company.

CBER will move to the FDA White Oak campus in Silver Spring, Maryland.

A new report from PhRMA outlines potential growth trajectories affecting the biopharmaceutical industry.

ThioBridge linker technology to attach different payloads to a range of antibodies

Biotechnology developer American CryoStem and Rutgers University partner on stem-cell platform technology development.

uniQure appoints a new COO and vice president, Medical affairs.

The Advanced Tissue-engineered Human Ectypal Network Analyzer project team is developing realistic human organs for testing.

Eli Lilly will present early-stage data regarding cancer therapies at AACR 2014.

Merck promotes internal managers to head Merck Millipore and Consumer Health Divisions.

Sun Pharma acquisition of Ranbaxy Laboratories will create the fifth-largest specialty generics company in the world.

Sun Pharma acquisition of Ranbaxy Laboratories will create the fifth-largest specialty generics company in the world.

European scientists have discovered a method to improve the efficiency of the pharmaceutical production through plant biotechnology.

New research finds that recurrent head and neck tumors have gene mutations that could be vulnerable to the cancer drug dasatinib.

Immunovaccine reports enhanced cancer vaccine combination therapies at 2014 AACR Annual Meeting.

Sanofi and Genzyme to resubmit FDA application for approval of Lemtrada, for the treatment of relapsing forms of multiple sclerosis.

Novartis delivers 2 million treatments of its pediatric antimalarial to Zambia in collaboration with Malaria No More's Power of One campaign.

RCA opens a new office in Warsaw, Poland.

Baxter announces plans to split into two independent companies by mid-2015.

Pfizer intends to submit a biologics license application for its investigational Meningococcal B vaccine candidate, Bivalent rlp2086, to FDA by mid-2014.

XstalBio Analytics' approach to vaccine analysis and formulation is aimed at understanding the antigen– adjuvant interaction.

FDA approves Xolair (omalizumab) for the treatment of a rare skin disease known as chronic idiopathic urticarial.

Novartis has launched the prefilled syringe formulation of Lucentis (ranibizumab) in Germany, with other markets to follow throughout 2014. The prefilled syringe formulation has been specifically designed for intraocular injection to enhance patient safety and convenience for the treating clinician.

Looking to improve patient access to new medicines, EMA creates a pilot project to explore an adaptive licensing approach with real medicines in development.

FDA clarifies recommendations for injectable drug products packaged in vials and ampules.